ArticleSaudi medical journal2025
Segmentation with artificial intelligence and automated calculation of the corpus callosum index in multiple sclerosis.
Article in Saudi medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Brain Atrophy and Cognitive Impairment in Primary and Secondary Progressive Multiple Sclerosis Cohort-Similar Progressive MS Phenotype.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo determine the corpus callosum index (CCI) differences between chronic phase multiple sclerosis (MS) patients and healthy individuals and to evaluate the corpus callosum segmentation in MS patients using artificial intelligence technologies. The CCI can be reliably measured on magnetic resonance imaging (MRI) and has been proposed as a possible marker of brain atrophy in MS.
methodsIn this study, 150 MS patients (disease duration 12.6±5.9 years) and 150 healthy control subjects were scanned. Corpus callosum index was manually measured from the mid-sagittal slices on MRI. A deep learning architecture-based U-Net model was used for automatic corpus callosum segmentation from 2D brain MRI.
resultsThe CCI score was calculated as mean 0.274 in the patient group and 0.382 in the control group (
conclusionCorpus callosum index is a method with high sensitivity and specificity in respect of determining corpus callosum atrophy in patients with MS in the chronic phase. Artificial intelligence technologies such as segmentation, machine learning, and deep learning to determine corpus callosum atrophy were seen to be successful in MS patients and the automatically calculated CCI score was successful in showing atrophy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.